Epcoritamab Combinations for Non-Hodgkin's Lymphoma
(EPCORE™ NHL-2 Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied. Trial details include: * The treatment duration for each participant depends upon which arm of treatment they are assigned to. * The visit frequency for each participant depends upon which arm of treatment they are assigned to, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks. * All participants will receive active drug; no one will be given placebo. Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned. Participants who receive standard treatments will have intravenous (IV) infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have had chemotherapy, radiation therapy, or major surgery within 4 weeks before starting the trial, and certain other treatments like CAR-T therapy are also restricted.
What data supports the effectiveness of the drug combination including Epcoritamab for treating non-Hodgkin's lymphoma?
Research shows that bendamustine, when combined with other drugs like rituximab, has been effective in treating non-Hodgkin's lymphoma, with high response rates in patients whose disease was difficult to treat. This suggests that combining bendamustine with other drugs, like Epcoritamab, could also be effective.12345
Is Epcoritamab and its combinations safe for treating Non-Hodgkin's Lymphoma?
Bendamustine, a drug often used in combination with others for treating lymphoma, has been studied for safety. In trials, it showed some side effects like mucositis (mouth sores), gastroenteritis (stomach issues), and skin reactions, but serious side effects were less common. Overall, it was considered safe when used in specific doses, but patients with pre-existing kidney issues should be cautious.46789
What makes the Epcoritamab combination treatment unique for Non-Hodgkin's Lymphoma?
The Epcoritamab combination treatment is unique because it includes a novel drug, Epcoritamab, which is a bispecific antibody designed to engage the immune system to target and destroy cancer cells. This approach is different from traditional chemotherapy regimens, which primarily focus on directly killing cancer cells, and it may offer a new option for patients with Non-Hodgkin's Lymphoma.23101112
Eligibility Criteria
This trial is for adults with B-cell Non-Hodgkin Lymphoma who are in relatively good health (ECOG PS score of 0-2), have measurable disease, and proper organ function. They must not have had certain treatments like bispecific antibodies or CAR-T therapy recently, no active infections like TB or hepatitis, and no history of HIV. Participants should use effective birth control.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive varying doses of epcoritamab to assess safety and determine the most appropriate dose
Dose Expansion
Participants receive the selected dose of epcoritamab to assess preliminary efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Bendamustine
- Carboplatin
- Cisplatin
- Cyclophosphamide
- Cytarabine
- Dexamethasone
- Doxorubicin
- Epcoritamab
- Gemcitabine
- Oxaliplatin
- Prednisone
- Rituximab
- Vincristine
Bendamustine is already approved in United States, European Union, Canada, Japan for the following indications:
- Chronic lymphocytic leukemia
- Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
- Non-Hodgkin lymphoma
- Multiple myeloma
- Chronic lymphocytic leukemia
- Non-Hodgkin lymphoma
- Chronic lymphocytic leukemia
- Non-Hodgkin lymphoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Genmab
Lead Sponsor
Dr. Jan van de Winkel
Genmab
Chief Executive Officer since 2010
PhD in Immunology, University of Utrecht
Dr. Judith Klimovsky
Genmab
Chief Medical Officer since 2019
MD, University of Copenhagen
AbbVie
Industry Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois